Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis

Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis

Abstract Background Second-line treatment for urothelial carcinoma (UC) patients is used if progression or failure after platinum-based chemotherapy occurs or if patients are cisplatin-unfit. However, there is still no widely accepted treatment strategy. We aimed to analyze the effectiveness and saf...

Full description

Bibliographic Details
Main Authors: Huitao Wang, Jianhe Liu, Kewei Fang, Changxing Ke, Yongming Jiang, Guang Wang, Tongxin Yang, Tao Chen, Xin Shi
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Urology
Subjects:
Urothelial carcinoma
Cisplatin-ineligible
Second-line
Meta-analysis
Online Access:https://doi.org/10.1186/s12894-019-0560-7

Internet

https://doi.org/10.1186/s12894-019-0560-7

Similar Items